63,219 Shares in Qiagen N.V. $QGEN Bought by The Manufacturers Life Insurance Company

Key Points

• The Manufacturers Life Insurance Company bought 63,219 Qiagen shares worth approximately $2.52 million, while institutional investors collectively own about 70% of the company.
• Analysts remain broadly cautious: Qiagen has an average “Hold” rating and a consensus price target of $43.34, with targets ranging from $38.60 to $45.50.
• Qiagen exceeded quarterly expectations, reporting $0.62 in EPS and $535.04 million in revenue; the company also increased its annual dividend to $0.35 per share.

The Manufacturers Life Insurance Company purchased a new stake in Qiagen N.V. (NYSE:QGEN - Free Report) in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 63,219 shares of the company's stock, valued at approximately $2,518,000.

Several other institutional investors have also added to or reduced their stakes in QGEN. Boston Partners acquired a new position in shares of Qiagen in the 3rd quarter valued at $179,450,000. Norges Bank acquired a new stake in Qiagen during the 4th quarter worth about $166,500,000. Dimensional Fund Advisors LP acquired a new stake in Qiagen during the 3rd quarter worth about $58,079,000. Price T Rowe Associates Inc. MD grew its stake in Qiagen by 12.1% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 8,429,424 shares of the company's stock valued at $379,072,000 after purchasing an additional 906,589 shares during the last quarter. Finally, Deutsche Bank AG grew its stake in Qiagen by 9.7% during the 4th quarter. Deutsche Bank AG now owns 7,907,801 shares of the company's stock valued at $355,614,000 after purchasing an additional 697,342 shares during the last quarter. Institutional investors and hedge funds own 70.00% of the company's stock.

Analyst Ratings Changes

QGEN has been the subject of a number of recent research reports. Kepler Capital Markets set a $38.60 price target on shares of Qiagen and gave the stock a "hold" rating in a research report on Thursday, June 25th. Weiss Ratings lowered Qiagen from a "hold (c-)" rating to a "sell (d+)" rating in a research note on Friday, May 29th. Berenberg Bank set a $45.50 price target on shares of Qiagen and gave the stock a "hold" rating in a report on Tuesday, July 14th. Stifel Nicolaus set a $40.00 price objective on shares of Qiagen in a research report on Friday. Finally, Citigroup reaffirmed a "hold" rating on shares of Qiagen in a report on Monday, May 18th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and an average target price of $43.34.

Qiagen Price Performance

Shares of Qiagen stock opened at $42.28 on Friday. The business has a 50 day simple moving average of $39.43 and a two-hundred day simple moving average of $41.69. Qiagen N.V. has a 12 month low of $32.53 and a 12 month high of $57.81. The stock has a market capitalization of $8.71 billion, a P/E ratio of 21.66, a PEG ratio of 4.21 and a beta of 0.63. The company has a debt-to-equity ratio of 0.49, a current ratio of 3.21 and a quick ratio of 2.57.

Qiagen (NYSE:QGEN - Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The company reported $0.62 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.60 by $0.02. Qiagen had a return on equity of 14.24% and a net margin of 19.49%.The firm had revenue of $535.04 million for the quarter, compared to analyst estimates of $527.50 million. During the same period in the previous year, the company posted $0.60 earnings per share. The business's revenue was up .2% on a year-over-year basis. Qiagen has set its FY 2026 guidance at 2.430- EPS. As a group, analysts predict that Qiagen N.V. will post 2.43 EPS for the current fiscal year.

Qiagen Increases Dividend

The firm also recently announced an annual dividend, which was paid on Tuesday, July 14th. Shareholders of record on Tuesday, July 7th were paid a dividend of $0.35 per share. This is a boost from Qiagen's previous annual dividend of $0.26. The ex-dividend date of this dividend was Tuesday, July 7th. This represents a yield of 90.0%. Qiagen's dividend payout ratio is presently 17.95%.

Qiagen Company Profile

Qiagen NV NYSE: QGEN is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company's solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company's product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.

Want to see what other hedge funds are holding QGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Qiagen N.V. (NYSE:QGEN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source